Drugs in Baby Trials 'Safe': AIIMS

The All India Institute of Medical Sciences (AIIMS) where 49 babies died in clinical trials conducted at the facility said Tuesday, that the drugs used in the tests were "safe," according to a report.

But the hospital, the state-run All-India Institute of Medical Sciences, said it was conducting an in-house inquiry into the trials, which started in the beginning of 2006 and are ongoing.

Sudden Infant Death Syndrome - Overview
Sudden Infant Death Syndrome is death of a baby, under one year of age that occurs in sleep and cannot be explained.

"All the studies had undergone scientific scrutiny and had all the required regulatory and ethical approvals," the hospital said in a statement, according to the Press Trust of India news agency.

The institute said the infants died because they had "high-risk and serious disease conditions," the report said.

The hospital denied that the children in the trials came solely from poor families, a concern raised by a non-profit group that had sought information about the trials through a freedom-of-information request.

Breast Feeding - The Flow
Interactive section of Medindia explains how the Breast Milk starts to flow

"There was no question of targeting any socioeconomic group selectively," the hospital statement said.

The hospital said more details would be provided after it completed the inquiry into the trials, which included drugs marketed by the US arm of Swiss-based Novartis and by US-based Shire Human Genetic Therapies.

Environmental Birth Defects - Chemical Factors - Biological Sources - Diagnosis - Treatment - FAQs
Birth defects caused due to environmental teratogens like drugs, microorganisms or exposure to radiation are called as environmental birth defects.

Some 4,142 babies admitted to the hospital have been in clinical trials since January 1, 2006, more than half of them under the age of one, said the Uday Foundation for Congenital Defects and Rare Blood Groups, which filed the request for information.

The non-profit's founder Rahul Verma said the group hoped to publicise the need for better regulation of India's booming outsourced clinical trial business, estimated at about 120 million dollars last year.

India has become a popular destination for clinical research because of its huge population, varied demographic profile and low costs. Trials here cost 40 to 60 percent of what they would in developed countries.

Consulting firm Ernst & Young has said the outsourced clinical research market in India, which is growing at 25 percent annually, could reach two billion dollars by 2010.

Source-AFP
THK/L